Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further evaluation of these mice showed that tenascin-X is an important regulator of collagen deposition in vivo, suggesting a novel mechanism of disease in this form of EDS.
|
16278880 |
2005 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-Throughput Screening for CYP21A1P-TNXA/TNXB Chimeric Genes Responsible for Ehlers-Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia.
|
31229653 |
2019 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tenascin-X deficiency in autosomal recessive Ehlers-Danlos syndrome.
|
15793839 |
2005 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Complete deficiency of TNX in humans leads to a recessive form of Ehlers-Danlos syndrome (EDS), and TNX haploinsufficiency is a cause of hypermobility type EDS.
|
18335242 |
2008 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
LHGDN |
Our results indicate that the observed alterations in elastic fibers are specific for hypermobility type EDS patients with mutations of TNX.
|
15733269 |
2005 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that TNXB is a functional candidate gene for EDS, we suggest that compound heterozygosity for the identified TNXB variants may have caused the EDS-like phenotype in the affected dog.
|
31365140 |
2019 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetically determined deficiency of tenascin-X causes the connective tissue disease Ehlers-Danlos syndrome.
|
15558324 |
2005 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin-X is important for the proper deposition of collagen fibers in dermis and patients with a tenascin-X deficiency suffer from Ehlers Danlos syndrome.
|
15094123 |
2004 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.
|
23284009 |
2013 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the limited awareness among geneticists and the challenge of the molecular analysis of the TNXB gene, the TNX-deficient type EDS is probably to be under diagnosed.
|
27582382 |
2017 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated.
|
11642233 |
2001 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This case highlights the utility of targeted exome sequencing for the diagnosis of congenital diseases showing genetic heterogeneity, and the importance of attention to gastrointestinal perforation in patients with tenascin-X deficient type EDS.
|
25772043 |
2015 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin X (TNX) deficiency is a rare type of EDS, defined as classical-like EDS (clEDS), since it phenotypically resembles the classical form of EDS, though lacking atrophic scarring.
|
31731524 |
2019 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three point mutations in TNX gene were found to be associated with hypermobility type EDS and one of such mutations is the V1195M mutation at the 7th fibronectin Type III domain (TNXfn7).
|
20853426 |
2010 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin-X, collagen, and Ehlers-Danlos syndrome: tenascin-X gene defects can protect against adverse cardiovascular events.
|
23830591 |
2013 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with tenascin-X (TNX)-deficient type Ehlers-Danlos syndrome (EDS) do not exhibit delayed wound healing, unlike classic type EDS patients, who exhibit mutations in collagen genes.
|
29291401 |
2018 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heterozygosity for TNXB mutations causing haploinsufficiency of TNX may be associated with the mild "hypermobility form" of EDS, which principally affects small and large joints.
|
29734195 |
2018 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unlike other subtypes, tenascin-X-related Ehlers Danlos syndrome is caused by an extracellular matrix protein deficiency rather than a defect in fibrillar collagen or a collagen-modifying enzyme, and the understanding of the disease mechanisms is limited.
|
24380766 |
2014 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some variants that cause autosomal-recessive congenital adrenal hyperplasia (CAH) also cause hypermobility type Ehlers-Danlos syndrome (EDS) due to the monoallelic presence of a chimera disrupting two flanking genes: CYP21A2, encoding 21-hydroxylase, necessary for cortisol and aldosterone biosynthesis, and TNXB, encoding tenascin-X, an extracellular matrix protein.
|
27297501 |
2016 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tenascin-X represents the first EDS susceptibility gene that does not code for a fibrillar collagen or collagen-processing enzyme.
|
20649799 |
2010 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An overlapping phenotype of Osteogenesis imperfecta and Ehlers-Danlos syndrome due to a heterozygous mutation in COL1A1 and biallelic missense variants in TNXB identified by whole exome sequencing.
|
26799614 |
2016 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular defects in extracellular matrix proteins, including collagen (type I, III, and V) and tenascin X are associated with different forms of EDS.
|
16583246 |
2006 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the reported cardiovascular abnormalities in other EDS types and the excessive haematoma formation after mild trauma in TNX-deficient individuals, we investigated whether cardiovascular or coagulation abnormalities occur in these patients.
|
15366699 |
2004 |
Ehlers-Danlos Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the study of these diseases has brought new insights into the molecular pathogenesis of EDS by implicating genetic defects in the biosynthesis of other extracellular matrix (ECM) molecules, such as proteoglycans and tenascin-X, or genetic defects in molecules involved in intracellular trafficking, secretion and assembly of ECM proteins.
|
22353005 |
2012 |
Ehlers-Danlos Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complete deficiency of the extracellular matrix glycoprotein tenascin-X (TNX) leads to recessive forms of Ehlers-Danlos syndrome, clinically characterized by hyperextensible skin, easy bruising and joint hypermobility.
|
23768946 |
2013 |